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Abstract 
Ins(11;X)(q23;q28q12) and ins(X;11)(q28;q23q23) 
are found so far in acute myelomonocytic leukaemia 
and carries a poor prognosis.  
The genes implicated in this disease are KMT2A and 
FLNA. 
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Identity 
The ins(X;11)(q28;q23q23) rearrangement is a form 
of ins(11;X)(q23;q28q12). The two  
chromosome anomalies are variants of each other, 
they lead to the formation of the same fusion gene 
KMT2A/FLNA. 
Clinics and pathology 
Disease 
Acute myelomonocytic leukaemia (FAB-M4) 
Phenotype/cell stem origin 
Poorly defined, only three cases described to date, 
see Table 1 (De Braekeleer et al., 2009; Matveeva et 
al., 2015; Lentes et al., 2016). 
Epidemiology 
All 3 patients were boys, aged 5 to 13 months. 
Cytology 
Bone marrow aspirates demonstrated 
hypercellularity, blasts show typical AML-M4  
features - high basophilic cytoplasm without Auer 




CNS Diagnosis Survival Karyotype KMT2A/FLNA 
1 5 mo/M 22 yes M4-AML 2 mths ins(11;X)(q23;q28q12) Intron 9 / exon 16 
2 7 mo/M 81 no M4-AML 3 mths +6,ins(X;11)(q28;q23q23) 





108 Unknown M4-AML 1 mth del(X)(q12),+del(X)(q12),+8,ins(11;X)(q23;q28q12),+19 Exon 11 / exon 11 
Table 1.  General characteristics and treatment course of patients with KMT2A/FLNA  
CNS: CNS involvement; M4-AML: Acute myelomonocytic leukaemia; KMT2A/FLNA breakpoints 
Reference: (1) De Braekeleer et al., 2009; (2) Matveeva et al., 2015; (3) Lentes et al., 2017. 
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Figure 1. (A) - the probe hybridized to interphase nuclei displayed two normal KMT2A copies and one additional copy of 5'-
KMT2A. (B) - when hybridized to metaphase, the probe displayed the additional copy of KMT2A 5'-portion translocated to 
chromosome X (Matveeva et al., 2015). 
 
Cytogenetics 
ins(11;X)(q23;q28q12) or ins(X;11)(q28;q23q23) 
with KMT2A rearrangement. 
Genes 
KMT2A at 11q23, FLNA at Xq28 
Prognosis 
Poor prognosis (see Table 1): all described patients 
died either from the disease progression (De 
Braekeleer et al., 2009; Matveeva et al., 2015) or 
from multiple organ failure (Lentes et al., 2016).  
In one patient, there was no remission; and he died 2 
months after diagnosis of disease progression.  
In the second case, a complete remission (CR) was 
obtained; there was two relapses; a bone marrow 
transplantation (BMT) 8 months after diagnosis from 
MUD, but the patient died on day +100 after BMT 
of disease progression. In the third case, there was a 
CR; but the patient died 38 days after diagnosis of 
multiple organ failure. 
Cytogenetics 
Cytogenetics morphological 
ins(X;11)(q28;q23q23) is cryptic 
Probes 
MLL dual color break apart rearrangement probe 
Additional anomalies 
Sole abnormality in one case, accompanied with 
trisomy 6 in one case, and disomy X, deletion 
del(X)(q12), trisomy 8 and trisomy 19 (complex 
karyotype) in the third case. 
Genes involved and 
proteins 





KMT2A gene consists of 37 exons encoding a 3969 
amino-acid nuclear protein with a molecular weight 
of nearly 431 kDa. 
Protein 
431 kDa; contains two DNA binding motifs (a AT 
hook and Zinc fingers), and a DNA methyl 
transferase motif; wide expression; nuclear 
localization. KMT2A gene encodes a transcriptional 
coactivator that plays an crucial role in regulating 
gene expression during early development and 
hematopoiesis. 
FLNA (filamin A) 
Location Xq28 
DNA/RNA 
FLNA gene consists of 48 exons encoding a 2647 
amino-acid protein with a molecular weight of 
280739 Da. 
Protein 
280739 Da; belongs to the filamins family of high 
molecular mass structural proteins; contains N-
terminal actin-binding domain; widely expressed; 
found in cytoplasm and cell cortex; involved into cell 
trafficking and actin cytoskeleton organization (Kim 
et al., 2011). Filamin A is an actin crosslinking 
phosphoprotein of the peripheral cytoplasm and 
interacts with Pho proteins. FLNA is crucial in many 
processes involving cytoskeletal reorganization (e.g. 
proliferation, differentiation, and apoptosis). It plays 
an important role in mitotic spindle function and is 
required for the G2/M cell cycle (Lentes et al., 2016). 
Germinal mutations 
Germline FLNA missense mutations are associated 
with otopalatodigital syndrome (OPD) spectrum of 
skeletal disorders. OPD is X-linked dominant and 
lethal in male patients. These mutations lead to a 
gain-of-function of filamin A (Clark et al., 2009).  
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On the other hand, loss-of-function FLNA mutations 
manifest as disorders of neuronal migration, also 
leading to early prenatal death in male patients 
(Kasper et al., 2013). 




KMT2A/FLNA fusion gene contains 5'-portion of 
KMT2A and 3'-portion of FLNA. Breakpoints are 
various in both genes (Table 1). In the first case, the 
KMT2A/FLNA fusion showed a breakpoint in intron 
10 of KMT2A and intron 19 of FLNA resulting in an 
in-frame fused mRNA (De Braekeleer et al., 2009). 
In the second one, an additional copy of 5' KMT2A 
inserted into the long arm of the X chromosome 
resulting in an in-frame KMT2A/FLNA fusion gene 
with breakpoints in intron 9 of KMT2A and exon 16 
of FLNA (Matveeva et al., 2015). And, in the third 
case, the breakpoint junction was localized in exon 
11 of KMT2A and exon 11 of FLNA. However, a 
potentially functional transcript was generated by 
alternative splicing, where KMT2A exon 10 was 
spliced in-frame to the truncated FLNA exon 117 
(Lentes et al., 2016). 
Transcript 
KMT2A/FLNA fusion transcripts were detected by 
RT-PCR in all cases (De Braekeleer et al., 2009; 
Matveeva et al., 2015; Lentes et al., 2016). It is 
notable that in two cases DNA junction was out-of-
frame; nevertheless, functional transcripts were 
produced by alternative splicing (see above) either 
by intron retention (Matveeva et al., 2015) or by 
using a new splice acceptor site (Lentes et al., 2016). 
Detection 
KMT2A/FLNA fusion genes were detected by LDI-
PCR (De Braekeleer et al., 2009; Matveeva et al., 
2015; Lentes et al., 2016). 
Fusion protein 
Oncogenesis 
Probably, the fusion KMTA/FLNA has an 
oncogenic potential by functioning as gain-of-
function mutants of KMT2A causing an upstream 
constitutive activation that promotes myeloid 
transformation and leads to AML. In all 
publications, due to lack of material, the existence of 
a functional protein has not been proven (Lentes, 
2017). 
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